Success Story: NIW Approved Without RFE for a Biomedical Science Researcher Advancing Clinical Research and Disease Mechanism Studies
Client’s Testimonial:
"Thank you again for all your help and guidance. I really appreciate it!"
On August 7th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for an Assistant Professor in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Assistant Professor
Country of Origin: Peru
State of Residence at the Time of Filing: Kentucky
Approval Notice Date: August 7th, 2026
Processing Time: 6 months, 8 days (Premium Processing Upgrade Requested)
Case Summary:
Biomedical science plays an important role in improving how complex diseases are studied, diagnosed, and treated, especially when research connects clinical medicine with diverse patient populations and disease mechanism investigation. In this case, the client’s work focused on developing clinical research study protocols and examining disease mechanisms to support earlier diagnosis, improved treatment strategies, and better health outcomes for patients affected by aging-related conditions and infectious diseases.
The client earned an M.D. and built a career combining clinical medicine, biomedical science research, clinical study development, and public health-focused disease investigation. At the time of filing, the client was conducting research in a U.S.-based academic medical setting, with work focused on understanding disease processes and improving diagnosis and treatment of complex medical conditions.
North America Immigration Law Group (NAILG) presented the proposed endeavor as an effort to advance biomedical research by developing clinical research study protocols and investigating disease mechanisms to improve diagnosis, treatment, and health outcomes for patients affected by aging-related conditions and infectious diseases.
At the time of filing, the client had authored 12 peer-reviewed journal articles and 4 abstracts (including 2 first-authored abstracts), which had collectively received 998 citations. The record also included at least 5 completed peer reviews, research support from Pfizer Inc. and the National Institutes of Health, and 4 recommendation letters, including 3 independent advisory opinions. One expert noted:
"In summary, [Client's] rare combination of scientific skill, leadership, and public health vision makes her an irreplaceable contributor to the biomedical science community."
Rather than presenting these metrics as isolated academic achievements, the petition demonstrated that the client’s work had practical value for clinical research, disease surveillance, and treatment-related decision-making. The filing also explained that at least 5 of the client’s papers ranked among the most highly cited Clinical Medicine articles for their publication years, including 1 paper in the top 0.1% and 4 papers in the top 10%.
To demonstrate significance, we showed that independent researchers relied on the client’s work in subsequent studies across multiple areas of medicine and public health, including infectious diseases, respiratory conditions, immune system function, aging-related health issues, and broader population health research.
Ultimately, this approval recognized the value of the client’s continued research in improving clinical research protocols, strengthening early diagnosis and treatment strategies, and supporting better outcomes for patients facing infectious disease and aging-related health challenges in the United States.